Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
ENTA is in the long-term up 260% in 4 years.
Description: Enanta Pharmaceuticals, Inc., a biotechnology company, is engaged in the development of small molecule drugs for the infectious disease field. Its product portfolio includes ABT-450, a protease inhibitor that is in Phase III clinical trials for the treatment of hepatitis C virus (HCV); ABT-493, a next-generation protease inhibitor for HCV infection; EDP-239, an NS5A inhibitor for HCV infection; Cyclophilin inhibitor, which are in preclinical development stage for HCV infection treatment; and Nucleotide Polymerase inhibitor program for HCV infection. The company also develops Bicyclolide antibiotic products comprising EDP-788 for the treatment of methicillin-resistant Staphylococcus aureus bacteria. It has collaboration and license agreements with Novartis Institutes for BioMedical Research, Inc.; and AbbVie Inc. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.
|Shares Outstanding||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||36.42%||Sales Growth - Q/Q||-25.98%||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||47.08%||ROE||51.63%||ROI|
|Current Ratio||8.98||Quick Ratio||Long Term Debt/Equity||Debt Ratio||0.09|
|Gross Margin||Operating Margin||82.62%||Net Profit Margin||64.48%||Dividend Payout Ratio|
|Cash From Financing Activities||2.26 M||Cash From Investing Activities||-100.46 M||Cash From Operating Activities||93.25 M||Gross Profit|
|Net Profit||28.75 M||Operating Profit||48.56 M||Total Assets||245.88 M||Total Current Assets||177.78 M|
|Total Current Liabilities||19.79 M||Total Debt||180 K||Total Liabilities||21.67 M||Total Revenue||57.37 M|
|High 52 week||126.37||Low 52 week||65.41||Last close||90.01||Last change||-1.7%|
|RSI||53.85||Average true range||3.99||Beta||1.06||Volume||182.38 K|
|Simple moving average 20 days||2.14%||Simple moving average 50 days||-2.93%||Simple moving average 200 days||4.69%|
|Performance Week||2.31%||Performance Month||5.72%||Performance Quart||-12.74%||Performance Half||16.94%|
|Performance Year||-14.59%||Performance Year-to-date||27.08%||Volatility daily||2.78%||Volatility weekly||6.21%|
|Volatility monthly||12.73%||Volatility yearly||44.1%||Relative Volume||295.56%||Average Volume||212.25 K|
|New High||0.99%||New Low|
2019-09-12 09:48:04 | Is Enanta Pharmaceuticals NASDAQ:ENTA A Risky Investment?
2019-08-21 07:30:00 | Enanta Pharmaceuticals to Present at the Baird 2019 Global Healthcare Conference
2019-08-07 12:37:52 | Enanta Pharmaceuticals, Inc. ENTA Q2 2019 Earnings Call Transcript
2019-08-07 02:05:39 | Edited Transcript of ENTA earnings conference call or presentation 6-Aug-19 8:30pm GMT
2019-08-06 17:55:09 | Enanta Pharmaceuticals ENTA Q3 Earnings Surpass Estimates
2019-08-02 08:51:00 | Enanta’s HCV Collaboration Partner AbbVie receives Approval by the European Commission for MAVIRET™ glecaprevir/pibrentasvir to Shorten Treatment Duration to Eight Weeks for Treatment-Naïve HCV Patients with Compensated Cirrhosis
2019-07-11 09:00:01 | Enanta Pharmaceuticals ENTA Upgraded to Strong Buy: Here's What You Should Know
2019-06-14 14:06:11 | Enanta's Respiratory Virus Drug Aces Midstage Study
2019-06-14 11:12:07 | How Much Did Enanta Pharmaceuticals, Inc.'s NASDAQ:ENTA CEO Pocket Last Year?
2019-06-14 09:51:28 | UPDATE 1-Enanta's lung infection therapy succeeds in mid-stage trial
2019-06-14 06:00:00 | Enanta Pharmaceuticals Announces Topline Results Showing EDP-938 Achieved its Primary and Secondary Endpoints in its Phase 2a Human Challenge Study in Healthy Adults Infected with Respiratory Syncytial Virus RSV
2019-06-10 16:00:00 | Enanta Pharmaceuticals to Present at Two Upcoming Investor Conferences
2019-06-10 08:00:00 | AbbVie's MAVIRET™ now listed on the Nova Scotia and Manitoba formularies
2019-05-30 08:00:00 | AbbVie's MAVIRET™ now listed in New Brunswick
2019-05-15 11:11:03 | Do Enanta Pharmaceuticals's NASDAQ:ENTA Earnings Warrant Your Attention?
2019-05-14 16:01:00 | Enanta Pharmaceuticals to Present at Upcoming Investor Conference
2019-05-08 00:02:11 | Edited Transcript of ENTA earnings conference call or presentation 7-May-19 8:30pm GMT
2019-05-07 21:00:10 | Enanta Pharmaceuticals, Inc. ENTA Q2 2019 Earnings Call Transcript
2019-05-07 17:25:09 | Enanta Pharmaceuticals ENTA Beats Q2 Earnings Estimates
2019-05-07 16:16:26 | Enanta Pharmaceuticals: Fiscal 2Q Earnings Snapshot
2019-05-02 14:22:17 | Here’s What Hedge Funds Think About Enanta Pharmaceuticals Inc ENTA
2019-04-15 09:40:02 | VKTX or ENTA: What to Expect from Revenue Growth in 2019
2019-04-15 08:05:54 | What Are Analysts Recommending for VKTX and ENTA?
2019-04-11 09:00:00 | AbbVie's MAVIRET™ now reimbursed in Quebec
2019-04-04 10:00:00 | AbbVie Announces New Formulary Listings for its Hepatitis C Treatment MAVIRET™
2019-04-01 09:25:01 | The Zacks Analyst Blog Highlights: Celgene, Puma, Exelixis, Enanta and Sage
2019-03-18 07:30:00 | Enanta Pharmaceuticals Completes Enrollment in Two Ongoing Phase 2 Studies
2019-03-11 07:30:00 | Enanta Pharmaceuticals to Present at Two Upcoming Investor Conferences
2019-02-15 07:35:00 | Factors of Influence in 2019, Key Indicators and Opportunity within BCE, Nektar Therapeutics, Hormel Foods, Enanta Pharmaceuticals, MongoDB, and Regal Beloit — New Research Emphasizes Economic Growth
2019-02-06 22:49:54 | Edited Transcript of ENTA earnings conference call or presentation 6-Feb-19 9:30pm GMT
2019-02-06 20:43:08 | Enanta Pharmaceuticals Inc ENTA Q1 2019 Earnings Conference Call Transcript
2019-02-06 17:10:10 | Enanta Pharmaceuticals ENTA Lags Q1 Earnings and Revenue Estimates
2019-02-06 16:07:13 | Enanta Pharmaceuticals: Fiscal 1Q Earnings Snapshot
2019-01-30 10:31:03 | Enanta Pharmaceuticals ENTA Earnings Expected to Grow: Should You Buy?
2019-01-22 12:09:11 | Do You Like Enanta Pharmaceuticals, Inc. NASDAQ:ENTA At This P/E Ratio?